Background
To compare OCs(oral contraceptives) + metformin and OCs alone for metabolic effects in nonobese polycystic ovary syndrome (PCOS) patients.
Methods
The search was performed in PubMed, EMBASE, the Cochrane Library and http://clinicaltrials.gov for all published studies up to 30 April 2022 and was limited to English‐language articles. All randomized controlled trials (RCTs) comparing OCs + metformin and OCs alone for reproductive‐age women with PCOS were included. Data were processed using Revman 5.3 software.
Results
Of 396 studies identified, 14 RCTs were included for analysis comprising 707 women. OCs+metformin significantly modified fasting glucose (MD = −0.21 [95% confidence interval (CI) = −0.31, −0.12], p < .00001) and fasting insulin (MD = −2.54 [95%CI = −4.04, −1.04], p = .0009) at study completion compared with OCs alone in nonobese PCOS subjects. There was no statistic difference in the homoeostasis model assessment of insulin resistance (HOMA‐IR), high‐density lipoprotein (HDL), low‐density lipoprotein (LDL), total cholesterol or triglycerides at study end between the two groups.
Conclusions
Metformin, via its positive effects on insulin clearance, in combination with OCs, improved glucose metabolism and offered a good treatment alternative in nonobese women with PCOS.
Objective
To compare 1‐ and 2‐day drug administration interval between mifepristone and misoprostol for second‐trimester pregnancy termination and provide evidence‐based recommendations.
Methods
Search strategy: the search was performed in Pubmed, EMBASE, and Cochrane Library for the relevant published studies from their establishment to March 2020. Selection criteria: randomized controlled trials (RCTs) comparing 1‐ and 2‐day time interval of mifepristone‐misoprostol for termination of pregnancy during second‐trimester pregnancy were considered. Data were processed using Revman 5.3 software.
Results
Meta‐analyses of three RCTs showed no significant difference was reported in the induction‐to‐abortion time and successful abortion rate between 1‐ and 2‐day mifepristone and misoprostol intervals. Statistical difference was not identified in the induction‐to‐abortion time between the two drug administration intervals in nulliparous or parous women.
Conclusions
Both 1‐ and 2‐day dosing intervals between mifepristone and misoprostol are suitable for clinical use for second‐trimester medical termination of pregnancy.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.